What is the purpose of this 10-Q/A filing?

This filing is an amendment (10-Q/A) to Vertex Pharmaceuticals Inc./MA's original Quarterly Report (10-Q) for the period ending March 30, 1996. Amendments are typically filed to correct errors, provide updated information, or include disclosures that were omitted from the initial filing.

What specific financial information is being amended or updated?

The provided text is a directory listing of the filing and does not contain the specific financial data or details of the amendments. To understand the precise changes, one would need to access and review the content of the amendment document itself.

Why would an investor need to pay attention to an amendment?

Amendments can be significant for investors as they may revise previously reported financial results, provide new material information about the company's operations, or clarify uncertainties. Ignoring amendments could lead to an incomplete or inaccurate understanding of the company's financial position and performance.

Where can I find the actual financial data for Vertex Pharmaceuticals from this filing?

The provided text is only the directory structure for the SEC filing. To access the detailed financial statements, management's discussion and analysis, and the specific amendments, you would need to consult the full text of the 10-Q/A filing, likely available through the SEC's EDGAR database or financial data providers.

VRTX 10-Q Quarterly Report Q1 FY1996 — Revenue, Net Income, EPS

Summary

This filing represents an amendment to Vertex Pharmaceuticals Inc./MA's Quarterly Report (10-Q) for the period ending March 30, 1996. As an amendment, it suggests that the company is providing updated or corrected information relevant to its financial performance and operations during that quarter. Investors should be aware that this filing may contain revisions to previously reported figures or disclosures, potentially impacting their understanding of the company's financial health and strategic direction. Further review of the specific changes within the amendment is crucial for a comprehensive analysis.

Key Highlights

1Filing is an amendment to the 10-Q for the period ending March 30, 1996.
2The amendment was filed on May 20, 1996.
3This indicates potential corrections or additional disclosures to the original quarterly filing.
4Investors should carefully review the changes from the original 10-Q.
5The filing pertains to Vertex Pharmaceuticals Inc./MA (VRTX).

VERTEX PHARMACEUTICALS INC / MA Quarterly Report (Amendment) for Q1 Ended Mar 31, 1996

Summary

Key Highlights

Frequently Asked Questions